Ascendis Pharma A (ASND) Debt to Equity (2021 - 2025)
Ascendis Pharma A (ASND) has disclosed Debt to Equity for 5 consecutive years, with -$4.72 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 39.36% to -$4.72 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.72 through Dec 2025, up 39.36% year-over-year, with the annual reading at -$4.72 for FY2025, 39.36% up from the prior year.
- Debt to Equity hit -$4.72 in Q4 2025 for Ascendis Pharma A, up from -$7.79 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.52 in Q4 2022 to a low of -$7.79 in Q4 2024.
- Historically, Debt to Equity has averaged -$2.74 across 5 years, with a median of -$2.81 in 2023.
- Biggest five-year swings in Debt to Equity: skyrocketed 1176.12% in 2022 and later plummeted 285.25% in 2023.
- Year by year, Debt to Equity stood at $0.12 in 2021, then soared by 1176.12% to $1.52 in 2022, then tumbled by 285.25% to -$2.81 in 2023, then plummeted by 177.37% to -$7.79 in 2024, then surged by 39.36% to -$4.72 in 2025.
- Business Quant data shows Debt to Equity for ASND at -$4.72 in Q4 2025, -$7.79 in Q4 2024, and -$2.81 in Q4 2023.